Evidence map›Paper›PMID 31718595›Full record

ArticleBMC cancer2019

EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.

Liqiong Xue, Hongzhu Yan, Ying Chen, Qifa Zhang, Xin Xie, Xiaoying Ding, Xiaojing Wang, Zhongqing Qian, Feng Xiao, Zhiyi Song and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. International journal of molecular sciences · 2023
    Article
  5. Article
  6. Review
  7. Expression ofMolecular medicine reports · 2022
    Article
  8. Review
  9. Article
  10. Oncology letters · 2021
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Liqiong XueDepartment of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Hongzhu YanDepartment of Pathology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ying ChenDepartment of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Qifa ZhangDepartment of Urology, Department of Endocrinology and Metabolism, Shanghai Traditional Chinese Medicine-Integrated hospital, Shanghai university of Traditional Chinese Medicine, Shanghai, China.
Xin XieDepartment of Urology, Department of Endocrinology and Metabolism, Shanghai Traditional Chinese Medicine-Integrated hospital, Shanghai university of Traditional Chinese Medicine, Shanghai, China.
Xiaoying DingDepartment of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaojing WangAnhui Clinical and Preclinical Key Laboratory of Respiratory Disease, Bengbu Medical College, Bengbu, China.
Zhongqing QianAnhui Clinical and Preclinical Key Laboratory of Respiratory Disease, Bengbu Medical College, Bengbu, China.
Feng XiaoDepartment of Pathology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhiyi SongDepartment of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yijie WuDepartment of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yongde PengDepartment of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Huanbai XuDepartment of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. huanbaixu@126.com.
Shanghai Jiao Tong University · CNShanghai University of Traditional Chinese Medicine · CNBengbu Medical College · CN

Funding

Key scientific and technological project of Songjiang District 18sjkjgg40Natural Science Foundation of China 81400776Natural Science Foundation of China 81500603Natural Science Foundation of Shanghai 19ZR1440800Shanghai Municipal Commission of Health and Family Planning General Project 201840290Shanghai Pujiang Program 15PJD033Shanghai Science and Technology Committee Youth Sailing Program 14YF1411800Shanghai Shenkang hospital development center for chronic disease prevention and control project SHDC 12015304Shanghai Three-year Action Plan for Promoting Clinical Skills and Innovative Ability of Municipal Hospitals 16CR4025A
6 · The paper itself

Abstract

backgroundThe incidence of papillary thyroid carcinoma (PTC) has been increasing worldwide in recent years. Therefore, novel potential therapeutic targets for PTC are urgently needed. Enhancer of zeste homolog 2 (EZH2), a methyltransferase belonging to PRC2, plays important roles in epigenetic silencing and cell cycle regulation. EZH2 overexpression has been found in several malignant tumor tissues, while its expression and function in PTC are largely unknown.

methodsSixty-five cases of PTC tissue confirmed by pathology and 30 cases of normal thyroid tissue adjacent to PTC tissue were collected from patients undergoing surgical treatment, between February 2003 and February 2006. We investigated the clinic pathologic significance of EZH2 expression using Realtime-PCR and IHC in 65 human PTC tissues and 30 normal thyroid tissue samples. The EZH2 expression in human PTC cell lines (K1 and W3) and the normal thyroid follicular epithelial cell line Nthy-ori 3-1 was analyzed by Western blotting and Realtime PCR. The expressions of ERα and ERβ in cell lines were analyzed by Realtime PCR.The tumor cell biological behavior was evaluated by CCK8 assay, colony formation assay, transwell migration assay and xenograft tumors model.

resultsHigher rate of EZH2 expression was found in PTC tissues than in normal thyroid tissues, EZH2 expression is associated with lymph node metastasis and recurrent. Inhibition of EZH2 in PTC cell lines downregulates cellular proliferation and migration. PTC is a disease with high incidence of female and E2-ERα upregulates EZH2 expression.

conclusionsThese results suggest a potential role of EZH2 for the PTC growth and metastasis. As a novel therapy, a pharmacological therapy targeting EZH2 has full potential in treatment of PTC.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAnimalsCase-Control StudiesCell Line, TumorCell MovementCell ProliferationDisease Models, AnimalEnhancer of Zeste Homolog 2 ProteinEstrogen Receptor alphaFemaleHeterograftsHumansImmunohistochemistryMaleEnhancer of Zeste Homolog 2 ProteinESR1 protein, humanEstrogen Receptor alphaEZH2 protein, humanEnhancer of zeste homolog 2Estrogen receptor alphaMigrationPapillary thyroid carcinomaProliferation

Identifiers

PMID31718595
PMCPMC6852908
OpenAlexW2985594258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.